Chemotherapy

What is Chemotherapy?

Chemotherapy is a group of toxic drugs that kill cells (mesothelioma, other cancers, and healthy cells) by damaging their DNA. Chemotherapy is a cytotoxic therapy, meaning it kills cells. Chemo drugs target rapidly growing cancer cells, but they can also affect healthy cells that grow rapidly such as blood cells. The effect of these drugs on both cancer and normal cells often causes chemo side effects.

Alimta (Pemetrexed) and Cisplatin

As of this writing, the only FDA approved chemotherapy for mesothelioma is a combination of Alimta (pemetrexed) and cisplatin. In February 2004, the Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma in combination with cisplatin for patients whose disease is either inoperable or who are not otherwise candidates for curative surgery. Patients who take this chemo regimen are often prescribed folic acid and vitamin B12 supplement to help reduce side effects from the chemotherpay. Patients are usually prescribed corticosteroids to reduce the risk of skin rashes as well.

The recommended dose of pemetrexed is 500 mg/m administered as an intravenous infusion over 10 minutes on day 1 of each 21-day cycle together with cisplatin at a dose of 75 mg/m infused over 2 hours beginning 30 minutes after the pemetrexed infusion.

The Clinical Trial that Approved Alimta (Pemetrexed) and Cisplatin

There was one key clinical trial that led to the FDA approval of this regimen for mesothelioma. Two hundred twenty-six pleural mesothelioma patients were randomized to receive pemetrexed and cisplatin, while 222 patients were randomized to receive cisplatin alone. The primary study end point was survival. Median survival times were 12.1 months for the pemetrexed plus cisplatin treatment group and 9.3 months for the cisplatin alone group.

Median time to progression (regrowth of tumor) was longer in the pemetrexed/cisplatin arm of the study, 5.7 months versus 3.9 months. This means that the mesothelioma patients who received both drugs had their tumors return a median of 1.8 months longer versus those who only got one drug.

Like most chemo drugs, pemetrexed kills blood cells so the most common adverse events were neutropenia, fatigue, leukopenia, nausea, dyspnea, and vomiting.

On February 4, 2004, pemetrexed was approved by the FDA in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is inoperable or who are otherwise not candidates for curative surgery.

Related Posts

First-Line Chemotherapy for Peritoneal Mesothelioma- The same drugs doctors use to treat pleural mesothelioma can provide effective chemotherapy for peritoneal mesothelioma, too. Japanese researchers reviewed the cases of 29 peritoneal mesothelioma patients. These patients had first-line treatment with cisplatin and pemetrexed between 2001 and 2016. The results suggest these drugs are safe and potent chemotherapy for peritoneal mesothelioma. The finding may help doctors and patients make better treatment decisions. Treating Malignant Mesothelioma Malignant mesothelioma is a membrane cancer. It usually occurs in one of two places. About 80 percent of mesothelioma tumors arise on the membrane that surrounds the lungs (the pleura). This is called pleural mesothelioma.  About 20 percent of the 2,500 cases of mesothelioma diagnosed in the US each year are peritoneal. Peritoneal … Continue reading First-Line Chemotherapy for Peritoneal Mesothelioma »

Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment- A bacteria-based immunotherapy vaccine for mesothelioma may improve the odds of surviving the disease by boosting the effects of chemotherapy.  That is the word from the latest clinical trial of CRS-207 headed by researchers at the National Cancer Institute. Thirty-five inoperable patients received the immunotherapy vaccine for mesothelioma along with standard mesothelioma chemotherapy. Eighty-nine percent of them experienced either a full or partial response to the treatment combination.  CRS-207 Immunotherapy Vaccine for Mesothelioma CRS-207 is based on a modified version of Listeria monocytogenes. The bacterium is best known for causing the food borne illness Listeriosis. In CRS-207, the bacteria has been changed so it cannot make patients sick. The immunotherapy vaccine for mesothelioma uses the bacteria to trigger a powerful … Continue reading Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment »

Mesothelioma Chemotherapy with Avastin Helps Pain, Neuropathy- New evidence suggests that supplementing standard mesothelioma chemotherapy with Avastin (bevacizumab) may lead to less pain. It may also reduce the risk of another mesothelioma complication called peripheral neuropathy. That word comes from a newly-published study involving several French hospitals. The study is a follow-up to the French-led MAPS study from 2016. The MAPS study showed that performing mesothelioma chemotherapy with Avastin – in addition to the standard chemotherapy drugs – improved mesothelioma survival by 23 percent. Now it looks like the three-drug combination can also help mesothelioma patients live longer with fewer side effects. Mesothelioma Complications and Side Effects Avastin is a VEGF inhibitor. It works by preventing the formation of blood vessels that feed a growing tumor. The … Continue reading Mesothelioma Chemotherapy with Avastin Helps Pain, Neuropathy »

Gel-Based Mesothelioma Treatment: A Novel Approach to Pleural Mesothelioma- Swiss scientists are developing a novel gel-based mesothelioma treatment for people with pleural disease. Early studies suggest it may be a safer way to deliver cancer-fighting drugs with fewer side effects. The gel-based mesothelioma treatment combines the chemotherapy drug cisplatin with a natural “glue” called fibrin. When the gel is applied during surgery, it can keep fighting tumors for months. Why Develop a Gel-Based Treatment? Cisplatin is a platinum-based drug. Together with pemetrexed (Alimta), it is one of the most common chemotherapy drugs for mesothelioma. In the past decade, doctors came up with a way to increase the effectiveness of cisplatin in people with peritoneal mesothelioma. These patients get chemotherapy the usual way. But they also get a rinse of … Continue reading Gel-Based Mesothelioma Treatment: A Novel Approach to Pleural Mesothelioma »

Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin- European doctors have tested a new spray-on cancer drug that could be another treatment option for people with advanced peritoneal mesothelioma. The drug is oxaliplatin. It is sold under the brand name Eloxatin. It is normally given by injection into a vein. But that can cause serious side effects, including stomach pain. A new study published in the European Journal of Surgical Oncology suggests there may be a more effective way to get the benefits of oxaliplatin. Researchers found that using it as a spray for advanced peritoneal mesothelioma extended survival with fewer side effects. PIPAC for Advanced Peritoneal Mesothelioma As Surviving Mesothelioma first reported last spring, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new way to deliver cancer medicines. … Continue reading Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin »

Ofev Shelved as a Treatment for Pleural Mesothelioma- It is official – the VEGF inhibitor Ofev is out of the running as a treatment for pleural mesothelioma. Hopes had been high for this drug after initial results showed a survival advantage. For the last two years, Ofev (nintedanib) was the subject of a large, international clinical trial. But now the leaders of that trial have published their Phase III trial results in The Lancet: Respiratory Medicine. They show that Ofev did not extend survival and is not an effective treatment for pleural mesothelioma. Why Hopes Were High for Ofev Ofev is an oral medication that stops cancer cells from producing a protein called VEGF. VEGF promotes the growth of blood vessels that help mesothelioma tumors grow. VEGF may … Continue reading Ofev Shelved as a Treatment for Pleural Mesothelioma »

Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines- Mesothelioma patients need to beware of low-volume centers that are less likely to follow mesothelioma treatment guidelines. That is the message from a new study based on data from the National Cancer Institute. The study was run by doctors at Cedars-Sinai Medical Center in Los Angeles. It shows that treatment centers that do not see a lot of mesothelioma cases are less likely to follow the life-saving mesothelioma treatment guidelines. As a result, patients treated in these lower-volume facilities tend to have shorter mesothelioma survival. What are the Mesothelioma Treatment Guidelines? Malignant pleural mesothelioma is a cancer that occurs on the membrane that surrounds the lungs. It is extremely rare and difficult to treat. Many hospitals and doctors never see … Continue reading Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines »

Metastatic Mesothelioma: Does Chemotherapy Work?- New research out of Pennsylvania suggested that not all people with metastatic mesothelioma will live longer with chemotherapy. Although chemotherapy is the primary treatment for malignant pleural mesothelioma, some types of metastatic mesothelioma appear to be less responsive than others. In some cases, the researchers say best supportive care may be a better option for preserving a patient’s quality of life. Three Mesothelioma Subtypes There are three histological subtypes of malignant pleural mesothelioma. The categories are based on how the cells look under a microscope. Cell type appears to influence how aggressive they are as metastatic mesothelioma. Cell type also factors into mesothelioma prognosis. Epithelioid mesothelioma is the most common cell type. Epithelioid cells tend to lack uniformity and may … Continue reading Metastatic Mesothelioma: Does Chemotherapy Work? »

Study Highlights How Genes Impact Mesothelioma Survival- A new National Cancer Institute study shines a light on some of the ways genes impact mesothelioma survival. It could have important implications for mesothelioma treatment. The study was led by prominent mesothelioma researcher Raffit Hassan, MD. It focused on genetic mutations that may make certain mesothelioma patients more sensitive to chemotherapy. Genes, Genotype, and Mesothelioma Treatment A mesothelioma patient’s unique collection of genes, including genetic mutations, is known as their genotype. Genes impact mesothelioma survival in a variety of ways. Tumor suppressor genes are supposed to help keep tumors from forming. People with mutations on these genes may be more likely to get malignant mesothelioma. Other genes influence the cancer’s ability to “hide” from detection by the immune system. … Continue reading Study Highlights How Genes Impact Mesothelioma Survival »

Combination Mesothelioma Therapy Begins Pivotal Trial- A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial »